In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $40.69 down -5.48% from its previous closing price of $43.05. In other words, the price has decreased by -$5.48 from its previous closing price. On the day, 2.47 million shares were traded. IONS stock price reached its highest trading level at $42.87 during the session, while it also had its lowest trading level at $40.66.
Ratios:
For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On July 01, 2025, Barclays Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $57.
On April 07, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $45.H.C. Wainwright initiated its Buy rating on April 07, 2025, with a $45 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 05 ’25 when Geary Richard S sold 10,000 shares for $42.86 per share. The transaction valued at 428,593 led to the insider holds 89,492 shares of the business.
PARSHALL B LYNNE bought 10,000 shares of IONS for $419,292 on Aug 06 ’25. On Aug 04 ’25, another insider, Schneider Eugene, who serves as the EVP, Chf Clinical Develop Ofcr of the company, sold 9,549 shares for $42.80 each. As a result, the insider received 408,701 and left with 51,507 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6861798400 and an Enterprise Value of 6176662016. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.87 while its Price-to-Book (P/B) ratio in mrq is 10.25. Its current Enterprise Value per Revenue stands at 6.543 whereas that against EBITDA is -24.206.
Stock Price History:
The Beta on a monthly basis for IONS is 0.28, which has changed by -0.14354873 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $50.43, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 3.39%, while the 200-Day Moving Average is calculated to be 15.87%.
Shares Statistics:
For the past three months, IONS has traded an average of 1.78M shares per day and 2256650 over the past ten days. A total of 159.20M shares are outstanding, with a floating share count of 155.51M. Insiders hold about 2.44% of the company’s shares, while institutions hold 103.84% stake in the company. Shares short for IONS as of 1752537600 were 12889193 with a Short Ratio of 7.25, compared to 1749772800 on 14225565. Therefore, it implies a Short% of Shares Outstanding of 12889193 and a Short% of Float of 10.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Ionis Pharmaceuticals Inc (IONS) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.67 and low estimates of -$1.15.
Analysts are recommending an EPS of between -$1.6 and -$2.58 for the fiscal current year, implying an average EPS of -$1.98. EPS for the following year is -$1.7, with 12.0 analysts recommending between $0.25 and -$3.68.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $131.97M this quarter.It ranges from a high estimate of $172.55M to a low estimate of $111.1M. As of the current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 15 analysts are estimating revenue of $148.88M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $131M.
A total of 22 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $837.85M, resulting in an average revenue estimate of $869.67M. In the same quarter a year ago, actual revenue was $705MBased on 25 analysts’ estimates, the company’s revenue will be $910.79M in the next fiscal year. The high estimate is $1.35B and the low estimate is $620.82M.
